Clinical Trial Update: Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluating the imaging characteristics of the PET tracer [18F]PI-2620 in Alzheimer's disease and progressive supranuclear palsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Progressive Supranuclear Palsy

Drugs mentioned

• [18F]PI-2620 (PI-2620)

Snippet

Sponsor: Life Molecular Imaging GmbH | Conditions: Alzheimer Disease, Progressive Supranuclear Palsy | Phase 1 | Status: COMPLETED